Navigation Links
Hospira Works With FDA to Help Avert Methotrexate Shortage; Shipping One Month's Supply of New Product Immediately and on Track to Ensure Sustainable Supply
Date:2/21/2012

LAKE FOREST, Ill., Feb. 21, 2012 /PRNewswire/ -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, announced today that it began shipping 31,000 vials of 1-gram methotrexate to U.S. hospitals and treatment centers on Monday, enough for one month's U.S. demand. In addition, Hospira continues to work closely with the U.S. Food and Drug Administration (FDA) to ensure that by mid-March the company will have produced enough supply of this life-saving drug for the full year.

(Photo: http://photos.prnewswire.com/prnh/20120221/CG56759)

Methotrexate is an injectable drug used to treat a variety of cancerous and rheumatologic conditions, including acute lymphoblastic leukemia (ALL), a childhood blood cancer.

Hospira began working to address the U.S. methotrexate shortage late last year by increasing production of the product when it first became aware of potential manufacturing challenges with other suppliers. Since then, Hospira has worked with the FDA to secure new supplies of the drug's active ingredient, and by mid-March will have manufactured enough 1-gram methotrexate to meet expected full market demand and also to begin establishing a safety stock to ensure patients and their families do not have to face fear of a shortage again. 

During an FDA briefing regarding progress on drug shortages today at the FDA's headquarters in White Oak, Md., Hospira CEO F. Michael Ball said:

"Commissioner Hamburg, ladies and gentlemen, it is an honor for me to be here today to represent Hospira and to show our continued support to our patients and U.S. hospitals. Hospira, headquartered in Illinois, is the largest provider of generic injectable products in the world, and I am proud to announce that through our continued partnership with the FDA, we will be able to avert a drug shortage crisis for methotrexate. 

"Accelerating the manufacture and delivery of methotrexate is a top priority for our entire company -- we have been, and will continue to do, everything we can to bring more product to the market. In fact, we have been working to address this issue since late last year when we first became aware of potential manufacturing challenges with other suppliers.

"As a result of those efforts, I'm thrilled to relay that, 24 hours ago, we began directly shipping 31,000 vials of new product -- enough to address more than a month's worth of demand -- and it is being received in hundreds of our nation's hospitals and treatment centers today. This represents the first step in our commitment to provide uninterrupted supply of this critical drug.

"Our ability to increase methotrexate production is contingent upon two things -- additional active ingredient and a streamlined system for product manufacture and release. Working in close cooperation with and approval from the FDA, we are able to achieve both. We worked aggressively and creatively to secure as much additional active ingredient as we could obtain by scouring the globe for FDA-approved active pharmaceutical ingredient (API) that we simply didn't have registered, but was in use by other companies who also manufacture the drug, to facilitate our qualification of the suppliers.

"As we speak, we are transporting well over 100 kilograms of new active ingredient to our manufacturing facility from locations around the world.

"Bolstered by our newly secured active ingredient, our manufacturing facility is literally working day and night to turn it into product.

"As a result, next week, we'll release an additional 34,000 vials. And by mid-March, we'll have enough product not only to meet the full market demand, but also to begin establishing safety stock to ensure patients and families never have to face this type of fear again.

"I specifically want to commend Commissioner Hamburg and the efforts by FDA's Center for Drugs and the Drug Shortage Program, led by Dr. Sandra Kweder and Captain Valerie Jensen, for the Agency's rapid response to the methotrexate shortage and for their tireless efforts to help address the challenges of drug shortages overall. Hospira supports, and has been providing, early warning notification to the Agency, and we believe this is a necessary step in our continued collaboration to prevent drug shortages. I also want to commend the members of Congress who have rallied support and pledged their commitment to combat drug shortages and the serious burden they place on patients and families.

"As everyone gathered here today knows, drug shortages in general have been a widespread and serious issue. Hospira is taking action to address shortages by investing hundreds of millions of dollars to increase capacity at existing facilities, build additional capacity and improve our manufacturing plants. We take our responsibility to this country and our patients seriously, and we look forward to working with key stakeholders to help prevent future shortages and avoid these types of frightening situations from recurring.

"Commissioner, we thank you for this opportunity, and on behalf of our 15,000 employees who are dedicated to the hospitals, healthcare providers, patients and families who need our products, we look forward to continuing our work with you to stop drug shortages."

Earlier today, the FDA issued a press release on progress addressing the methotrexate shortage. The press release can be accessed at the following link: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm292658.htm

About Hospira
Hospira, Inc. is the world's leading provider of injectable drugs and infusion technologies. Through its broad, integrated portfolio, Hospira is uniquely positioned to Advance Wellness™ by improving patient and caregiver safety while reducing healthcare costs. The company is headquartered in Lake Forest, Ill., and has approximately 15,000 employees. Learn more at www.hospira.com.


'/>"/>
SOURCE Hospira, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Hospira Announces Start of U.S. Phase III Biosimilar EPO Clinical Program
2. Hospira to Host Conference Call for Fourth-Quarter 2011 Results and 2012 Projections
3. Hospira to Present at the J.P. Morgan 30th Annual Healthcare Conference Jan. 10, 2012
4. Hospira Reports Third-Quarter 2011 Results
5. Hospira Announces Certain Preliminary Third-Quarter 2011 Results
6. Hospira to Host Conference Call for Third-Quarter 2011 Results
7. Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients
8. Hospira to Host 2011 Investor Day
9. Hospira to Present at the Morgan Stanley Global Healthcare Conference
10. Hospira Expands Board of Directors
11. Hospira Announces U.S. Approval of Solution Version of Gemcitabine Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 2017 On Wednesday, February 22, 2017, ... out of nine sectors finished the trading sessions in green, ... closing. Major US indices were also mixed at the close ... 5,860.63, slightly down by 0.09%; the Dow Jones Industrial Average ... 500 closed at 2,362.82, down 0.11%. This Thursday morning, Stock-Callers.com ...
(Date:2/23/2017)... 2017 ML Capital Group, Inc. (USOTC: MLCG) ... Highlife Tours , a Colorado -based cannabis ... Puration, Inc. (USOTC: PURA) to enter Colorado,s ... Colorado Highlife Tours acquisition announced today is intended to accelerate MLCG,s ... ...
(Date:2/23/2017)... Wash. and VANCOUVER, British Columbia ... (NASDAQ: OGXI ) today announced its year ... In January 2017, OncoGenex, and Achieve Life ... that they have entered into a definitive merger agreement ... transaction. Upon completion of the proposed merger, Achieve,s stockholders ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... Rare Disease Report®, which ... participating in Rare Disease Day events, hosted by the Rare Disease Legislative Advocates ... a website, weekly e-newsletter and quarterly publication, will be conducting interviews with patients ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... content provider for the National Institute for Health and Care Excellence ... organizations in the National Health Service (NHS) to search, order and purchase medical ...
(Date:2/23/2017)... ... 23, 2017 , ... Current Meditation , a new ... throughout the U.S. starting this spring. Current Meditation focuses on “meditation for the ... Current Meditation will be the first meditation concept in the U.S. offering franchising ...
(Date:2/23/2017)... ... February 23, 2017 , ... Top cosmetic and periodontal dentist ... today with a new Indiegogo campaign . Individuals are now able to contribute ... Los Angeles area, either as a participating patient or through an Indiegogo donation. The ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... and lobby of a new healthcare contact center in Georgia, PENETRON Specialty Products ... of the nation’s largest healthcare systems recently invested $51 million to purchase and ...
Breaking Medicine News(10 mins):